Monday, January 16, 3:15 - 4:30 PM
BuzZ Table 1: Deep Profiling of Ab Sequence-function Relationships by Deep Sequencing
Host: Timothy A. Whitehead, PhD, Associate Professor, Chemical & Biological Engineering, University of Colorado, Boulder
- Specificity profiling.
- Analysis of affinity and specificity in complete antibody repertoires
- Rapid and fine paratope profiling
BuzZ Table 8: Implementation Challenges for Machine Learning as a Tool for Antibody Discovery
Host: Christopher Negron, PhD, Principal Research Scientist, AbbVie, Inc.
- Current successes
- Experimental validation and POC
- Bottlenecks and challenges
- Needs from IT and solution providers
BuzZ Table 2: Beyond Injectable mAb Drug Products
Host: Christopher Mensch, Director, Drug Product, IGM Biosciences, Inc.
- Delivery Technologies for New Routes
- Dosage Form & Formulation Considerations
- Analytical Characterization
BuzZ Table 3: Cell Therapy Drug Product Development
Host: Bharathi Vellalore, PhD, Senior Scientist, Biotherapeutics Drug Product Development, Janssen
- Process considerations for manufacturing autologous and allogeneic cell therapy products
- Drug product considerations for hematological malignancies and solid tumor indications
- Clinical vs commercial supply chain needs: Integrated drug product design
BuzZ Table 7: Cell Therapy Process Development
Host: Kelly Kemp, PhD, Senior Director CMC, ViaCyte, Inc.
- Selection of raw materials
- Increasing cell yields
- Demonstrating comparability
BuzZ Table 4: Combining the Benefits of Academia and Industry: Get the Best of Both Worlds
Host: Bjørn Voldborg, MSc, Head, National Biologics Facility, DTU Bioengineering, Technical University of Denmark
- How to raise awareness at both ends?
- How to start-up?
- What are the needs?
- Funding and pricing/who will pay?
BuzZ Table 5: High Throughput—Multiplexed Technologies to Characterize Protein Interaction
Host: Peter Bell, PhD, Senior Director Assay & Platform Development
Host: Rebecca Cook, PhD, Research Scientist II, INanoBio
- Comparative methods for study of protein interactions—Pros/Cons
- Challenges in expression of functional proteins for protein interactions
- Screening of hundreds to thousands of protein interactions in parallel
- Antibody screening against large panels of targets or variants—affinity, specificity
- Detection methods—discussion of readouts—MS, SPR, fluorescence, reporter assays which are best?
BuzZ Table 6: Targeted Supplementation to Improve Protein Titer and Quality in CHO Cells
Host: Natalie McAdams, PhD, Manager Cell Biology, BioProduction R&D, Thermo Fisher Scientific
- How can supplements be applied to a bioproduction process to boost protein titer?
- What process parameters and supplements can impact protein quality?
- Lessons learned – what process parameters or supplements can have a negative impact on performance?
Friday, January 20, 8:00 - 9:00 AM
BuzZ Table 1: Purification Workflows to Support Protein Engineering
Host: Jeremy King, PhD, Senior Scientist, Amgen, Inc.
- Miniaturization strategies are needed to explore large sequence space
- Novel analytical techniques can distinguish good and bad molecules
- High-throughput purification strategies are needed to isolate correct variants from mixtures
- High-throughput non-antibody molecule purification strategies are lagging behind antibody platforms
BuzZ Table 2: Scalable Non-Protein A Affinity Purification Alternatives to Bridge Research and Manufacturing
Host: David W. Wood, Ph.D., Professor, Chemical and Biomolecular Engineering, The Ohio State University
- Laboratory scale affinity methods are effective and diverse, but are not generally considered scalable
- Development of new therapeutics might be streamlined by methods than can merge research and production
- What laboratory affinity methods could be scaled for manufacturing, and under what conditions?
- What are the primary hurdles for developing new non-Protein A affinity platforms clinical use?
BuzZ Table 3: High Capacity Chromatography Material for Virus Purification
Host: Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)
- Diffusion limitation of existing material
- How to meet selectivity and capacity
- Single vs multiple use
BuzZ Table 4: VHH: Challenges & Opportunities
Host: Andre Teixeira, PhD, Scientist, Specifica, Inc.
- Main challenges during VHH development
- Are they easier to develop than regular antibodies?
- Where and when should we use them
- Can they ever replace IgG?
BuzZ Table 5: Common Issues with Transient Protein Production
Host: Hosts: Richard Altman, MS, Field Application Scientist, Protein Expression, Biosciences Division, Life Sciences Solutions Group, Thermo Fisher Scientific
Host: Henry C. Chiou, PhD, Senior Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Host: Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
- What are the current challenges to transient protein production?
- How has the COVID-19 pandemic affected your workflow and productivity?
- How do we optimize the whole protein expression workflow process?
- How can we maintain volumetric yields while scaling transient expression up or down?
- What cell line(s) should we use and when?
- What parameters can impact the quality or physical attributes of transiently produced proteins?
BuzZ Table 6: Bispecific Antibodies from Bench to the Clinic
Host: Priya Hays, PhD, Technical Writer, Science Writer, Hays Documentation Specialists, LLC
- Clinical Development and Efficacy of BiTEs and BCMAs in Hematological Malignancies
- Immune Related Adverse Events
- Beyond CD3-CD19 Epitopes: Dual Affinity BsAbs and Tandem Diabodies
- Combination and Sequential Therapies
BuzZ Table 7: The Challenges and Opportunities for Treating
Low HER2 Expressing Cancers
Host: Rakesh Dixit, PhD, President & CEO, Bionavigen
Host: Robert J. Lutz, PhD, CSO, Iksuda Therapeutics
- Challenges of developing effective therapies against low HER2- cancers
- Unprecedented activity of Enhertu ( Trastuzumab Deruxtecan, a HER2 Targeting ADC in low HER2 breast cancer, ASCO recognition and FDA approval
- New and upcoming therapies to treat Enhertu refractory low HER2 expressing tumors